Dec 25, 2024 · PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha) is a Protein Coding gene. Diseases associated with PIK3CA include Megalencephaly-Capillary Malformation-Polymicrogyria Syndrome and Congenital Lipomatous Overgrowth, Vascular Malformations, And Epidermal Nevi.

Mar 3, 2025 · PIK3CA-related overgrowth spectrum (PROS) includes a group of genetic disorders that leads to overgrowth of various body parts due to changes (variants) in the gene PIK3CA. This gene is involved in making a protein that helps regulate cell growth, division and survival.

The PIK3CA gene provides instructions for making the p110 alpha (p110α) protein, which is one piece (subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3K). Learn about this gene and related health conditions.

Aug 15, 2013 · PIK3CA-related overgrowth spectrum (PROS) encompasses a range of clinical findings in which the core features are congenital or early-childhood onset of segmental/focal overgrowth with or without cellular dysplasia.

What is PIK3CA? PIK3CA is a gene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase. PIK3CA plays a role in the way cell growth, cell survival, and cell migration are controlled. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and may cause cancer as well as some rare diseases of abnormal growth.

May 15, 2019 · In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant (at a dose of 500 mg every 28 days and once on day 15) with placebo plus fulvestrant in patients...

PIK3CA is a crucial player in the PI3K/AKT signaling pathway that regulates essential cellular processes like growth, survival, and proliferation. It is estimated that PIK3CA mutations occur in approximately 30% of all breast cancer cases , with varying mutation rates across different molecular subtypes .

3 days ago · Gene mutations in PIK3CA, the catalytic subunit of phosphoinositide 3-kinases, are significantly associated with prognosis in breast cancer. This association suggests that breast cancer patients with PIK3CA mutations should receive PIK3CA mutant-specific treatment. This review aimed to investigate novel treatments for PIK3CA-mutant breast cancer. This study …

Mar 13, 2025 · PIK3CA mutations influence breast cancer progression by shaping tumor growth dynamics, metastatic potential, and treatment resistance. While often associated with a luminal phenotype and well-differentiated histopathology, their impact on disease trajectory depends on context. In HR+ breast cancers, PIK3CA alterations contribute to sustained ...

Mar 12, 2025 · Turner NC, Im S-A, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584-1596. U.S. Food and Drug Administration. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.